Compounds > idrabiotaparinux
Page last updated: 2024-08-03 05:43:50

idrabiotaparinux

Description

idrabiotaparinux: a biotinylated form of idraparinux with anticoagulant properties [MeSH]

Cross-References

ID SourceID
PubMed CID16202213
MeSH IDM0542155

Synonyms (6)

Synonym
774531-07-6
idrabiotaparinux
h44r6rjt3s ,
unii-h44r6rjt3s
idrabiotaparinux [who-dd]
Q27279616

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's14 (87.50)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (31.25%)5.53%
Reviews8 (50.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (18.75%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
beta-alanine
1
amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter		2012201212.0low000010
dalteparin
2
2012201212.0low100020
thiophenes
3
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent2009201213.7low000210
thiazoles
3
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2009201312.7low000120
biotin
16
biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite		2009201711.7high5004120
dabigatran
4
aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines		anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor		2009201313.0low000220
sanorg 34006
7
2009201711.7medium200250
vitamin k semiquinone radical
5
2009201411.2low100140
fondaparinux
3
amino sugar;
oligosaccharide sulfate;
pentasaccharide derivative		anticoagulant2009201710.7low000120
rivaroxaban
3
aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		2009201213.7low000210
apixaban
4
aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		2009201313.0low000220
betrixaban
1
benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		2009200915.0low000100
edoxaban
3
chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor		2009201312.7low000120
warfarin
5
benzenes;
hydroxycoumarin;
methyl ketone		2012201410.8low200050
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acute Disease0
1
2012201212.0low100010
Apoplexy0
3
2014201410.0low100030
Atrial Fibrillation0
5
2009201412.0low100230
Auricular Fibrillation0
5
2009201412.0low100230
Benign Neoplasms0
1
2010201014.0low000100
Bleeding0
4
2009201711.2low200130
Blood Clot0
2
2009201014.5low000200
Deep Vein Thrombosis0
5
2010201711.4low300140
Embolism, Pulmonary0
2
2012201212.0low100020
Hemorrhage0
4
2009201711.2low200130
Neoplasms0
1
2010201014.0low000100
Pulmonary Embolism0
2
2012201212.0low100020
Recrudescence0
2
2011201710.0low100020
Stroke0
3
2014201410.0low100030
Thromboembolism0
3
2014201410.0low100030
Thromboembolism, Venous0
2
2013201311.0low000020
Thrombosis0
2
2009201014.5low000200
Venous Thromboembolism0
2
2013201311.0low000020
Venous Thrombosis0
5
2010201711.4low300140

Safety/Toxicity (1)

ArticleYear
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1		2011

Dosage (4)

ArticleYear
Pentasaccharides for the treatment of deep vein thrombosis.
The Cochrane database of systematic reviews, , 12-02, Volume: 12		2017
Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
British journal of clinical pharmacology, , Volume: 75, Issue:5		2013
Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
Journal of thrombosis and haemostasis : JTH, , Volume: 8, Issue:4		2010
New anticoagulants for atrial fibrillation.
Seminars in thrombosis and hemostasis, , Volume: 35, Issue:5		2009